Ethereum (HYPE) Faces Market Headwinds as Microsoft Phases Out VBScript

• Microsoft is accelerating the removal of VBScript, warning that reliance on legacy tools like Slmgr.vbs for Windows activation could break in future OS updates .
• Zenbody RX launched a telehealth platform for compounded GLP-1 care, aiming to provide continuous clinician monitoring alongside medication management .
• Institutional investors remain bullish on Royalty Pharma, with major funds increasing stakes despite a consensus 'Buy' rating and mixed quarterly financial results .

Microsoft is warning enterprises that the deprecation of the legacy VBScript environment could disrupt critical Windows activation processes. The company is phasing out the language after nearly 30 years, requiring organizations to migrate to PowerShell for automation capabilities .

This transition is particularly urgent for IT teams managing large-scale deployments. The legacy Slmgr.vbs tool, used for managing product keys and licensing status, will cease to function once VBScript is fully removed .

Organizations must audit their current scripts and group policies to mitigate disruption. The recommended alternative is the PowerShell OSLicense module, which offers equivalent functionality for managing activation instances .

However, the migration presents significant challenges for enterprise IT departments. The OSLicense module currently requires Windows PowerShell 5.1 and is only available in client versions of Windows 11 following specific preview updates .

Full support for Windows Server is expected in the next major release, leaving a gap in compatibility for many server environments. Microsoft urges immediate action to prevent operational failures when legacy dependencies are finally removed .

How Does the New Telehealth Model Change GLP-1 Access?

Zenbody RX has entered the rapidly evolving weight-management sector with a new telehealth platform designed for compounded GLP-1 medications. The platform focuses on providing personalized, clinician-guided care rather than simple prescription fulfillment .

The initial rollout features compounded semaglutide and tirzepatide. Semaglutide targets the GLP-1 receptor pathway, while tirzepatide acts on both GIP and GLP-1 pathways to regulate appetite .

Licensed clinicians review patient responses and make clinically appropriate adjustments. The platform is structured to help patients understand their treatment and stay engaged in their long-term weight management journey .

This approach addresses the growing demand for structured, continuous support in weight management. Company leadership emphasizes that care should not end once medication is dispensed, positioning the service as a holistic treatment experience .

Zenbody RX plans to expand its service offerings beyond weight management in the coming months. Planned additions include hormone replacement and longevity peptides, reflecting a broader strategy to treat medication as one component of comprehensive care .

Why Are Institutional Investors Bullish on Royalty Pharma?

Institutional ownership in Royalty Pharma remains robust, with major funds like Invesco and the Royal Bank of Canada increasing their stakes. This bullish sentiment persists despite a reduction by the National Pension Service, which sold a portion of its holdings in the second quarter .

Wall Street maintains a consensus 'Buy' rating for the stock, with an average price target of $61.29. Analysts cite strong earnings beats and a recurring royalty business model that mitigates the high risks associated with biotech drug development .

Royalty Pharma reported second-quarter earnings of $1.32 per share, beating estimates of $1.27. However, revenue of $674.14 million missed expectations of $758.93 million, highlighting the mixed nature of recent financial performance .

The company maintains a healthy net margin of 32.14% and a return on equity of 30.01%. Its business model involves funding life sciences companies in exchange for future royalty payments on commercialized or late-stage therapies .

This structure generates consistent cash flow without the volatility of clinical trial outcomes. Major investment firms, including MIRAE ASSET and Invesco Ltd., have significantly boosted their exposure to the stock .

Despite the positive analyst outlook, insider activity showed some selling pressure. Executive Vice President Christopher Hite sold 150,000 shares under a pre-arranged plan, reducing his ownership by over 21% .

Total insider sales in the last quarter amounted to $22.5 million, though this activity was structured to avoid market impact. The company also declared a quarterly dividend of $0.235, yielding 1.6% annually .